Keywords: dose response modeling, montonicity, clinical trials
Many dose response modeling techniques rely on monotonicity assumptions and a wide dose range. In practice, the number of doses and the spacing of doses is often limited by budgets and other demands. This roundtable will discuss tradeoffs and issues in dose response modeling given the practical limitations often placed on clinical trials. What rules of thumb do you follow when it comes to number of doses in a clinical trial and the spacing of those doses? How frequently do you observe non-monotone responses and what statistical approaches do you use in these cases?